 Sarah Doernberg, MD
Dr. Sarah Doernberg is trained in Internal Medicine and is currently an Infectious Diseases fellow at UCSF. She is working with Drs Chip Chambers, Catherine Liu, and Lisa Winston and has a focus on hospital epidemiology and infection control.
 Carolina Haass-Koffler, PharmD
Dr. Carolina Haass-Koffler completed her doctoral degree in Pharmacy in the Pharmaceutical Science Pathway and she is currently working with Drs Selena Bartlett and Antonello Bonci in the Medication Development/Transitional Research group at the Ernest Gallo Clinic & Research Center.
Dr. Haass-Koffler's research interest is determining the physiological role of Corticotropin-releasing-factor binding-protein (CRF-BP), its interaction with its ligand (CRF) and receptors GPCRs. CRF-BP was originally thought to have simply a buffer role, preventing excessive levels of CRF during stressful events. However, we postulate that CRF-BP is not just a sink for CRF, but has an active role in the CRF-mediate processes and the potentiation of NMDA receptor signaling. Dr. Haass-Koffler is also interested in the effect of CRF-BP on psychiatric disorders and its role in reinstatement of cocaine and alcohol seeking behaviors.
 Susannah Kussmaul, MD
Dr. Susannah Kussmaul is a pediatrician who is interested in pharmacoepidemiology, specifically the judicious use of antibiotic therapy. She is working with Drs B. Joseph Guglielmo and Jay Tureen on a research project focusing on novel methods for treating intravascular-related infections in children. She is concurrently completing a fellowship in Pediatric Infectious Diseases.
 Roeben Munji, MD
Dr. Roeben Munji conducted his doctoral research in the field of neuroscience. He is currently working with Drs Roland Bainton and Richard Daneman on a research project focusing on identifying new genes and genetic pathways that regulate blood-brain barrier (BBB) function. The BBB is a cellular and molecular barrier that protects the brain from injury and disease by inhibiting entry of pathogens, immune cells and xenobiotics, including therapeutic drugs, into the brain. His aims are to expand the understanding of BBB biology and identify targets for manipulating BBB permeability for the treatment of BBB-associated neurological diseases and to enhance drug delivery to the brain.
 Connie Remsberg, MD
Dr. Connie Remsberg is a pharmacist that completed her Ph.D. in Pharmaceutical Sciences at Washington State University. She is currently working with Dr. Leslie Benet on clinical studies involving pharmacokinetics, drug transporters, and drug-drug interactions.
PAST FELLOWS:
 Adam Frymoyer, MD
Dr. Adam Frymoyer is a pediatrician and worked with Dr. Leslie Benet. He studied drug transporters and participated in clinical studies of antibiotics in children.
 Joshua Galanter, MD
Dr. Joshua Galanter is an internist with training in pulmonary and critical care medicine.
He worked with Dr. Esteban Burchard. The focus of his research is the interplay between genetics, the environment and drug response, especially among children from minority populations.
 Wendy Lorizio, MD, MPH
Dr. Wendy Lorizio is trained in medicine and epidemiology and is working with Drs Elad Ziv and Esteban Burchard.
Dr. Lorizio's research interests are cancer, genetic epidemiology and pharmacogenetics, with a particular focus on minority populations, especially Latinas. Her specific research project will be to study the interaction among genetic polymorphisms of the estrogen receptor alpha and beta genes, the CYP2D6 gene and serum biomarkers such as IGF-1 and osteocalcin as predictors of adverse effects from tamoxifen in women being treated for breast cancer. Dr Lorizio is also planning to study the decision process of women deciding whether to take tamoxifen and how CYP2D6 genotyping affects that decision.
|
